1<!DOCTYPE html>

Products & Services Patient Focused Services Patient Support Programs

Gaining Support for Patient Adherence Programs and Effective Resource Allocation to Drive Adherence

ID: PSM-349


13 Info Graphics

23 Data Graphics

360+ Metrics

5 Narratives

Pages: 46

Published: Pre-2019

Delivery Format: Shipped


License Options:

Buy Now



Dynamic shifts within the healthcare industry have caused a dramatic rise in patient influence. In turn, forward-looking companies have developed and launched robust adherence programs to inform patient decisions drive better outcomes.

But for most companies, gaining support and resources for adherence programs remains a persistent internal challenge.

Best Practices, LLC undertook this benchmarking research to uncover how leading pharma and biotech companies develop and manage their patient adherence programs. This report delivers benchmarks around adherence program structure, staffing, vendor management, investment, leadership, process and content generation trends.

This report also highlights key metrics for measuring adherence program effectiveness, and explores proven winning strategies for driving adherence through case examples.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Manufacturing; Consumer Products; Diagnostic; Medical Device; Chemical; Health Care; Clinical Research; Laboratories

Companies Profiled:
Abbvie; Alkermes; Amgen; Bayer; Biogen; Celgene; Eisai; Genentech; Janssen; Jazz Pharmaceuticals; LEO Pharma; OTSUKA; Sanofi; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma

Study Snapshot

Best Practices, LLC engaged 20 leaders with deep experience in managing patient adherence operations at 16 leading biopharmaceutical companies.

Key topics covered in this report include:

  • Examining Current and Future Staffing and Investment Trends
  • Structure, Process & Vendor Management: Examining Where Adherence Groups Report and Program Management Trends
  • Leadership: Activities and Channels
  • Adherence Programs: Strategic and Tactical Options
  • Measuring Strategy Effectiveness

Key Findings

Sample key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Staffing - Contractors and Consultants: On average, companies utilized four contracted FTEs for every in-house FTE, not including call centers.
  • Structure - Budget Allocation: Most large biopharma reported that they allocate budget for programs on a per product basis, while some small-medium biopharma take into account revenue of products.
  • Program Content - Two Major Groups: Activities within patient adherence groups are usually broken into two groups: financial activities to help patients receive access to the drugs and behaviorally-focused activities that influence the patients to stay on drug.

Table of Contents

I.Benchmark Class Profilep. 3
II.Key Findingsp. 6
III.Staffing & Investmentp. 10
IV.Structure, Process & Vendor Managementp. 16
V.Leadershipp. 25
VI.Adherence Programs: Strategic and Tactical Optionsp. 29
VII.Strategy Effectiveness Measurementsp. 39
VIII.About Best Practicesp. 46

    List of Charts & Exhibits

    I. Staffing & Investment: Examining Current and Future Trends for Adherence Talent and Budgets
    • Total number of full-time equivalent employees (FTEs) dedicated to adherence program design and management
    • Change in staffing trend over the past three years and anticipated staffing change in the next three years
    • Total investment into adherence program design and management and percentage of overall organization budget specifically allocated to adherence program design and management
    • Adherence program investment strategy
    • Investment into key patient adherence activities

    II. Structure, Process & Vendor Management: Examining Where Adherence Groups Report and Program Management Trends
    • Current new product development stage at which adherence group’s role begins and ideal stage at which it should actually begin
    • Organization structure of adherence team
    • Reporting relationship of staff tasked with adherence program design and management
    • Budget location for adherence design and management activities
    • Agencies/vendor partners providing the best experience in regards to strategy, design, implementation and management for adherence programs
    • Total number of vendors and agencies with whom adherence groups partner across all the supported brands
    • Percentage of adherence programs customized as per patient segments
    • Number of in-market adherence programs supported and number of programs in development

    III. Leadership: Activities and Channels
    • Role of adherence group with respect to person-to-person and digital interface adherence activities
    • Target audience for adherence programs

    IV. Adherence Programs: Strategic and Tactical Options
    • Integrated strategy addressing behavioral, socioeconomic and therapy nuances
    • Patient adherence program toolbox
    • Case example 1: Copay programs/insurance navigator - Decreasing cost-aversion through copay/coverage initiatives
    • Case example 2: One-on-one support - Connecting patients with HCP/nurse to overcome adherence barriers
    • Case example 3a: Community platform - Developing patient-lead programs to impact the community
    • Case example 3b: Community platform - Understanding and influencing adherence behavior through community
    • Case example 4a: Behavioral interventions - Increasing patient connections through behavioral interventions
    • Case example 4b: Behavioral interventions - SIMPLE method focuses on the individual needs of the patient through increased education about the medication
    • Case example 5: Gamification - Increasing immersion in brand, understanding of disease and importance of prescription, goals, competition

    V. Measuring Strategy Effectiveness
    • Overall effectiveness of patient adherence activities
    • Effectiveness of person-to-person adherence activities
    • Effectiveness of digitally-mediated adherence activities
    • Effective tactics for improving patient adherence
    • Primary advancement in patient adherence programs over the past several years having the most positive impact on improving medication adherence
    • Importance of different types of anonymized and aggregated patient data to the success of adherence programs